Energy News / Shareholders Foundation, Inc.

NASDAQ:BLCM Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Bellicum Pharmaceuticals Inc

Via: ReleaseWire

Updated 11:30 AM CDT, Tue, June 12,2018

An investigation on behalf of current long term investors in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:BLCM stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 06/12/2018 -- An investigation was announced forinvestors in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) concerning potential breaches of fiduciary duties by certain directors and officers of Bellicum Pharmaceuticals Inc.

Investors who are current long term investors in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ:BLCM stocks follows a lawsuit filed against Bellicum Pharmaceuticals over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:BLCM stocks, concerns whether certain Bellicum Pharmaceuticals directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of Texas the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that a substantial undisclosed risk of encephalopathy was associated with the Company's lead product candidate BPX-501, and that as a result of the foregoing, Bellicum's public statements were materially false and misleading at all relevant times.

On January 30, 2018, post-market, Bellicum Pharmaceuticals Inc announced "that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501", Bellicum Pharmaceuticals Inc's lead product candidate, "have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501." Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) declined to as low as $5.42 per share on February 6, 2018.

Those who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqblcm-long-term-shareholder-notice-investigation-of-potential-wrongdoing-at-bellicum-pharmaceuticals-inc-993018.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com